



100 Lancaster Ave.
Suite R215
Wynnewood, PA 19096

610.645.6796

www.curedm.com

Contact: Donna Morrow (CureDM)
donna@curedm.com

CureDM, Inc. Announces the Appointment of Stephen M. McLean to the Board of Directors

Chester, Pennsylvania., April 25, 2006 -- CureDM, Inc, a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin, announces the appointment of key advisor Stephen M. McLean to the Board of Directors. Founded in 2004 by Endocrinologists Claresa S. Levetan, MD, F.A.C.E and Rita El-Hajj, MD F.A.C.E., CureDM pursues the goal of developing an alternative treatment for diabetes through islet restoration.

With the discovery of a new therapeutic candidate and an innovative approach to treatment, CureDM is very science driven. "Our goal is to limit the speed of discovery only by the pace at which nature reveals her secrets," states President and CEO Loraine V. Upham, formerly of Eli Lilly and Company and Merck and Company. "Steve has an uncanny ability to facilitate progress and we are pleased to have him as a driving force on our team."

Mr. McLean is a managing director of Arena Capital Partners, LLC and is an active investor and board member of a number of private companies in the healthcare industry focusing on Life Sciences, Medical Devices and Information Services, including Agencourt Bioscience, the largest commercial genomic sequencing center. Mr. McLean was previously a founding partner of Merrill Lynch Capital Partners, Inc, and its successor, Stonington Partners, a leader in the development of the Leveraged Buyout Industry.

The addition of Mr. McLean to the board will provide assistance not only in the capitalization process, but also in the management of the project from a development standpoint. Human proIslet Peptide (HIP) is in the early stages of development, but shows great promise in human tissue culture studies. The goal is to achieve Investigational New Drug (IND) status through the FDA within the next 12 months.